ProfileGDS5678 / 1422902_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 82% 81% 82% 84% 84% 86% 83% 83% 83% 83% 82% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8825982
GSM967853U87-EV human glioblastoma xenograft - Control 26.0144882
GSM967854U87-EV human glioblastoma xenograft - Control 36.005982
GSM967855U87-EV human glioblastoma xenograft - Control 45.9813281
GSM967856U87-EV human glioblastoma xenograft - Control 55.9843582
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0414884
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0070184
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4528186
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0795883
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1748783
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0288383
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1818683
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8638582
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0046683